Moleculin Biotech, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule10b5-1 trading arrangement or a non-Rule10b5-1 trading arrangement (each as defined in Item408 of Regulation S-K under the Securities Exchange Act of1934, as amended).
On* May 6, 2026,we agreed to issue warrants to purchase100,000* shares of common stock with an exercise price of*$2.48* per share to an entity providing consulting services, which warrants will vest in12 equal monthly installments overone year, subject to the entity's continued provision of consulting services to the Company. The warrant was issued pursuant to the exemption from the registration requirements of the Securities Act of1933 available under Section4(a)(2) thereunder.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.